Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Common Equity (2020 - 2025)

Historic Common Equity for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to $165.1 million.

  • SAB Biotherapeutics' Common Equity rose 34732.42% to $165.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $165.1 million, marking a year-over-year increase of 34732.42%. This contributed to the annual value of $26.0 million for FY2024, which is 5467.74% down from last year.
  • Per SAB Biotherapeutics' latest filing, its Common Equity stood at $165.1 million for Q3 2025, which was up 34732.42% from $12.0 million recorded in Q2 2025.
  • SAB Biotherapeutics' 5-year Common Equity high stood at $165.1 million for Q3 2025, and its period low was $12.0 million during Q2 2025.
  • Its 5-year average for Common Equity is $40.5 million, with a median of $36.9 million in 2024.
  • Data for SAB Biotherapeutics' Common Equity shows a peak YoY increase of 34732.42% (in 2025) and a maximum YoY decrease of 7394.56% (in 2025) over the last 5 years.
  • Over the past 5 years, SAB Biotherapeutics' Common Equity (Quarter) stood at $38.5 million in 2021, then dropped by 19.43% to $31.1 million in 2022, then soared by 84.49% to $57.3 million in 2023, then crashed by 54.68% to $26.0 million in 2024, then skyrocketed by 535.65% to $165.1 million in 2025.
  • Its Common Equity was $165.1 million in Q3 2025, compared to $12.0 million in Q2 2025 and $21.4 million in Q1 2025.